AI Scientists, Stock Tumble, Patent Lawsuit, and New Partnerships
About this episode
The episode discusses advancements in AI for scientific research, stock market fluctuations in biotech, patent lawsuits, and new partnerships in the biopharma industry.
Agentic AI is growing in its applications. Google DeepMind and Edison are leveraging the growing capabilities by developing AI Scientists. These platforms are poised to streamline the scientific process, aiding human scientists with a variety of tasks. Meanwhile, despite positive data in its Phase III DMD therapy trial, Regenxbio’s stock fell for a variety of reasons. 10X Genomics and Harvard University are suing Element Biosciences over patents for a multiomics platform. Finally, Bristol Meyers Squibb is partnering with Hengrui Pharma to develop 13 early-stage programs with the potential to grow their investment to a predicted $15 billion in sales. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base : Google DeepMind and Edison Are Building the AI Scientist By Fay Lin, PhD, GEN Edge , May 19, 2026 StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate By Alex Philippidis, GEN Edge , May 17, 2026 10x Genomics, Harvard Target…
People in this episode
Host: Corinna Singleman, PhD
Guests: Alex Philippidis, Fay Lin, PhD, Uduak Thomas
Topics covered
- AI in science
- biotech news
- patent lawsuits
- biopharma partnerships
- stock market analysis
Keywords
- AI Scientists
- biotech
- patent lawsuit
- biopharma
- stock market
Mentioned in this episode
Organizations: Google DeepMind, Edison, Regenxbio, 10X Genomics, Harvard University, Element Biosciences, Bristol Meyers Squibb, Hengrui Pharma
More episodes of Touching Base
Explore listener stats, chart rankings, contacts and more on the Touching Base podcast page.